|
Subgroup
|
OS
|
PFSa
|
|---|
|
n
|
HR (95% CI)
|
P value
|
n
|
HR (95% CI)
|
P value
|
|---|
|
Total
|
10
|
0.47 (0.31 to 0.72)b
|
<0.001
|
11
|
0.87 (0.51 to 1.47)b
|
0.596
|
|
Subtotal by ethnicity
| | | | | | |
|
White
|
6
|
0.67 (0.47 to 0.95)b
|
0.026
|
7
|
1.27 (0.71 to 2.26)b
|
0.420
|
|
Asian
|
4
|
0.35 (0.19 to 0.64)b
|
0.001
|
4
|
0.43 (0.21 to 0.89)b
|
0.024
|
|
Subtotal by disease
| | | | | | |
|
Brain glioma
|
3
|
0.72 (0.52 to 0.99)b
|
0.045
|
–
|
–
|
–
|
|
Prostate cancer
|
–
|
–
|
–
|
3
|
1.25 (0.45 to 3.48)b
|
0.671
|
|
Esophageal cancer
|
–
|
–
|
–
|
2
|
1.50 (0.53 to 4.22)b
|
0.443
|
|
Subtotal by main pathology
| | | | | | |
|
Adeno
|
3
|
0.47 (0.14 to 1.61)b
|
0.228
|
7
|
1.01 (0.55 to 1.89)b
|
0.965
|
|
SCC
|
2
|
0.34 (0.13 to 0.93)b
|
0.035
|
2
|
1.50 (0.53 to 4.22)b
|
0.443
|
|
Glioblastoma
|
3
|
0.72 (0.52 to 0.99)b
|
0.045
|
–
|
–
|
–
|
- OS, overall survival; PFS, progression-free survival including any of relapse-free survival (RFS), disease-free survival (DFS), and metastasis-free survival (MFS); N, number of studies; HR, hazard ratio; CI, confidence interval; SqCa, squamous carcinoma; Adeno, adenocarcinoma.
- aPFS included any of the following: DFS, MFS or RFS.
- bThe HRs and 95% CIs of the analyzed studies were pooled by the random-effects model if the P value for heterogeneity was less than 0.10 or I2 was greater than 50%.
